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1. Introduction 
The notion that tumors arise from a rare population of cells with stem cell characteristics 
was first proposed more than a century ago when pathologists like Virchow and Cohnheim 
formulated the hypothesis that cancer results from the activation of embryonic-tissue 
remnants (Weiss 2000). Since then, advances in different fields have provided support to this 
original proposal that has led to the increasingly accepted yet controversial “cancer stem cell 
(CSC)” hypothesis that explains the development of multiple forms of human cancers 
(Wicha et al. 2006). The first experiments indicating the existence of these cells were 
performed in animal models in the 1970s where it was concluded that only a low percentage 
of transplanted murine lymphoma cells formed colonies in the spleen of recipient animals 
(Park et al. 1971a; Bruce and VAN DER 1963). Likewise, only a minimum number (1 in 100 
to 1 in 100,000) of murine myeloma cells were able to form colonies in in vitro experiments. 
This low in vivo and in vitro clonogenic potential of tumor cells was subsequently observed 
for cells isolated from human solid tumors and led to the proposal that only a restricted set 
of cells “tumor stem cells” that have the propensity to differentiate, give rise to the entire 
population of cells that are present in certain tumor (Hamburger and Salmon 1977). Over 
the last few years, the isolation, characterization and functional analysis of CSCs have been 
facilitated rapid advancements in tissue culture, cell sorting, transgenic animal models and 
mouse-xenografting techniques (Rasheed et al. 2010). These advances have generated 
considerable newer insights, and thus contributed in improving our knowledge of CSCs role 
in cancer and have made their selective targeting a focus of central attention for cancer 
therapy (Toda 2009; Dodge and Lum 2011). Nevertheless, the precise origin and functional 
properties of CSCs remains unclear or controversial in several aspects (Hill 2006). Cancers 
that contain a hierarchy of epigenetically distinct populations of tumorigenic and non-
tumorigenic cells might be more effectively studied and treated by focusing on the rare or 
cancer initiating (causing) cells (Singh et al. 2004). But this field will only achieve its promise 
if we carefully distinguish between cancers that follow a cancer stem cell model and those 
that do not (Vermeulen et al. 2008). Therapies designed to eliminate only a small 
subpopulation of cancer cells will likely not have a clinical impact on cancers in which 
tumorigenic cells represent most of the cancer cells in the patient (Huff et al. 2006; Massard 
et al. 2006). Additional testing of the cancer stem cell model will be required in different 
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cancers to determine what fraction of cases actually follow the model, and how often 
existing markers are informative. Such testing is likely to yield a complex picture involving 
differences between cancers that may vary between patients with the same cancer, in terms 
of the frequency of tumorigenic cells or tumor initiating cells. This is especially true for 
complex malignancies such as pancreatic ductal adenocarcinomas that are well recognized 
to be very heterogeneous in nature. Their can also be differences in the degree of 
hierarchical organization, and the extent to which markers can distinguish tumorigenic from 
non-tumorigenic cells. In this regard, the use of xenograft tumor models is considered an 
attractive approach for better understanding of tumorigenesis in vivo, the developmental 
relationship between cancer cells, and even new therapies. However, it is critical that such 
models be optimized for the engraftment of human cells if we are to draw conclusions 
regarding the frequency of tumorigenic cells. In this chapter, an attempt is made to revise 
and extend some current ideas regarding the CSC hypothesis, and how newer technologies 
such as systems and network biology can aid in this field.  
2. Cancer stem cell versus clonal selection hypothesis 
The fundamental concept of cancer stem cells came from early studies in leukemia and the 
blood forming hematopoietic stem cells (HSC). Seminal works by Till and McCulloch in the 
early 1960’s established the existence of bone marrow HSC capable of forming myelo-
erythroid colonies in the spleen of lethally irradiated hosts. These cells were later isolated by 
Weissman and his group where they showed that the cells were capable of self-renewal 
exhibiting multipotent differentiation giving rise to all the blood cell lineages (Spangrude et 
al. 1988). Studies in human leukemia using in vitro and in vivo colony-formation assays 
demonstrated that only a small subset of leukemia cells possess extensive proliferative 
capability, suggesting that leukemia may actually be derived from a small leukemic stem 
cell (LSC) population (Park et al. 1971b). This concept was further proved by the successful 
isolation of myeloid leukemia-initiating cells using cell surface phenotype CD34+CD38- and 
subsequent in vivo transplantation into severe combined immune-deficient (SCID) mice. 
Even though compelling evidence exists on the existence of stem like cancer cells, yet the 
hypotheses are considered controversial by purist believing in clonal evolution theory. In 
the following passages we will discuss the existing concepts and also demonstrate how 
newer technologies such integrated network and systems biology can help to understand 
these differences in a more comprehensive way.   
2.1 Cancer stem cell hypothesis 
It is well established that cancer is in essence a genetic disease that arises from sequential 
accumulation of mutations in oncogenes and tumor suppressor genes, leading to a 
malignant clone (Balmain 2001). If the CSC theory is correct, then the result of this 
accumulation of genetic hits is, at least, one cell with CSC features that can give rise to more 
CSCs and create more differentiated progeny (Buzzeo et al. 2007). At what stage in the 
process of malignant transformation this CSC arises, is highly disputed (Potten and Loeffler 
1990). An important aspect of the CSC model is the implication that in a malignancy with a 
defined set of genetic alterations, cells with a different malignant potential are present. In a 
tumor, both differentiated cells that have lost the capacity to propagate a tumor, and cells 
that retain a clonogenic capacity, exist. This implies that cells showing the same genotypic 
alterations can show a completely different potential to initiate a tumor in mice. Here we 
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first present evidence that this proposed difference in malignant potential is not as striking 
as it has been initially envisioned. It is believed that CSCs give rise to more differentiated 
progeny that have lost the ability for self-renewal and the capacity to initiate the formation 
of a tumor (Figure 1). This would imply that remnant regulatory mechanisms are present in 
cancer cells that guide the differentiation process in analogy to normal cell differentiation. 
Indeed, there are examples of malignant cells that are transformed in nonmalignant cells by 
non-genetical pathways such as epigenetic effects (Kim et al. 2010; Jaenisch and Bird 2003). 
There is growing body of evidence showing that one of the most studied epigenetic 
abnormalities in cancer, abnormal gene silencing associated with gene promoter DNA 
hypermethylation, is linked to key aspects of chromatin regulation of gene expression which 
maintains the state of embryonic stem (ES)/progenitor cells. This is a timely juxtaposition 
since there is also a growing body of data, suggesting that cancer “stem/initiating cells”, 
especially when they may dominate in the most aggressive forms of human tumors, have a 
gene expression signature reminiscent of ES cells. 
 
 
Fig. 1. Cancer stem cell hypothesis: In ideal situation normal hematopoietic stem cells give 
rise to progenitor cells that form differentiated cells. They can also self renew to give rise to 
normal cell counterparts that helps in retaining the stem cell number. However, during 
cancer progression multiple rounds of genetic insult/mutations in normal stem cells or 
progenitor cells, leads to a progressive loss of regulatory control networks that ultimately 
causes de-differentiation of these cells. De-differentiated cells can give rise to cancer stem 
cells that are different from normal progenitor or differentiated cells 
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Earlier studies have indicated that de-differentiated malignant cells can give rise to both 
malignant as well as benign cells. In these studies it was shown that mutations are not the 
only factors that predict  the malignant potential of cells (Bissell and LaBarge 2005). Other 
researchers have recorded that malignant squamous cell carcinoma cells could give rise to 
more differentiated, non-malignant offspring (Pierce and Wallace 1971). Similarly another 
study, showed that subcutaneous injection of embryonal carcinoma cells can give rise to 
teratocarcinomas, while the same cells injected into a blastocyst developed a normal chimeric 
mouse (Mintz 1965; Mintz and Illmensee 1975). Refining this concept, Hochendlinger et al., 
demonstrated that transfer of a nucleus from a melanoma cell into an oocyte (to generate 
embryonic stem cells) generated chimeric mice with a normal phenotype, despite the fact 
that a clear increase in cancer incidence was observed (Hochedlinger et al. 2004). This work 
suggests that the epigenetic profile, environmental factors and proteome of the cell cytoplasm 
of the oocyte influences the events at the time of nuclear transfer and can compensate for 
mutations to a large extent. This difference in epigenetic profile could also explain the 
variety in tumorigenic potential of CSCs and differentiated cells in a malignancy. Indeed 
there is some evidence showing that epigenetic differences between CSCs and more 
differentiated cells exist, as there is for example, a hypermethylation described for TGFβ-RII 
in the mammary carcinoma non-CSCs (Shipitsin et al. 2007). Although this suggests that 
purely genetic models of tumor selection could go hand in hand with the CSC hypothesis, 
yet several crucial issues remain and can only be answered through a clonal selection 
perspective that is discussed in the following passages. 
2.2 Clonal selection hypothesis 
Proponents of clonal selection theory claim that instead of stem cell theory, the hierarchical 
organization of a malignancy could be easily integrated in the classical clonal selection 
theory of Nowell (Nowell 1971; Nowell 1976; Nowell 1989). This theory views a malignancy 
as a clonally-derived cell population, which acquires new potentially advantageous 
mutations that give rise to new more rapidly proliferating clones. This leads to a process 
referred to as ‘tumor Darwinism’, which selects for the cell type most suitable for unlimited 
proliferation in the given environment (Sottoriva et al. 2010) (Different cell lineages and 
clonal cells generations depicted in Figure 2). When one integrates the CSC theory in this 
model, the selection pressure is predicted to act at the level of the CSC compartment, 
implying that de-differentiation in CSCs results in an increase in expansion of the CSCs due 
to self-renewal by symmetrical divisions. This does not mean, however, that certain features 
present only in the more differentiated cells in the tumor could not be the subject of 
selection, especially if this increases the expansion rate of the CSCs from which they are 
derived. For example, the more differentiated cells may provide the CSC from which they 
are derived and which they surround a possible advantage over other clones. In this respect 
one could think of growth factor production, promoting angiogenesis or the production of 
immunosuppressive cytokines. Although this suggests that purely genetic models of tumor 
selection could go hand in hand with the CSC hypothesis although several other crucial 
issues remains to be fully elucidated. 
3. Utilizing systems biology to understand cancer stems cells 
Systems approaches including but not restricted to computational modeling have proven of 
great utility in the study of cancer, with increasing power expected to continue to emerge in 
the future (Wang et al. 2007). Despite notable and significant challenges that remain, three 
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areas that have shown significant promise is in the mining of global gene/protein expression 
data sets to identify molecular signatures that can be used for identification of lineage 
differences in cells, diagnosis of disease and treatment selection (Araujo and McElwain 
2004a; Araujo and McElwain 2004b). 
 
 
Fig. 2. Tumor clonal selection theory: Stem cells with tumor initiating capacity give rise to 
more differentiated nontumorigenic offspring. During the process a selection pressure is 
predicted to act as tumor Darwinism (here depicted by different colors) that can be 
beneficial for the clone yellow’ or metastatic and cancerous (as shown in ‘red’) 
As with any complex biological system, cancer (including CSCs) can be interrogated at the 
genome/proteome-scale using integrated systems biology approaches. Systems approaches 
stress three concepts regarding biological information (i) there are two fundamental types of 
biological information — the digital information of the genome and the environmental 
information that is outside our DNA. (ii) this digital genome information encodes two types 
of biological networks — protein interactions and gene regulatory networks. Protein networks 
transmit and use biological information for development, physiology and metabolism. Gene 
regulatory networks — transcription factors and RNAs that regulate networks of other 
transcription factors and other RNAs —receive information from, for example, signal-
transduction networks, integrate and modulate it, and convey the processed information to 
networks of genes and proteins that execute developmental and physiological functions. In 
biological systems, these two types of networks are closely integrated. The organization of 
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these networks can be inferred from various different types of measurements including, for 
example, global measurements of dynamically changing levels of mRNAs and proteins 
during developmental and physiological responses, as well as large-scale measurements of 
protein–protein and protein–DNA interactions. (iii) the hierarchical levels of organization 
and information (for example, DNA, RNA and protein networks, cell signaling and 
metabolic networks, and organization and responses of organ systems). To understand 
biological systems, information must be gathered from as many information levels as 
possible and integrated them into models that generate testable hypotheses about how 
biological systems may function. 
 
 
Fig. 3. Systems biology: [Left panel] complex data sets, and complex networks, can rarely be 
understood using intuition, or traditional biological tools. Instead, an interdisciplinary 
approach, involving techniques from the mathematical, integrated/computational, physical 
and engineering sciences is required. To be fully effective such an approach needs to 
repeatedly traverse an interactive cycle of collaborative interaction between biological 
knowledge and the proposed hypothesis that has to be validated by robust experimentation. 
The obtained datasets can be constructed into networks that can be correlated to the 
available biological knowledge and analyzed in light of the hypothesis. [Right panel] life’s 
complexity pyramid showing hierarchy of structures from basic genomic information at the 
base to regulatory motifs, functional modules and large scale biological networks. The 
upward directed information is universal in nature while the information flow downstream 
of a network is cell/organism specific. Systems biology can help in understanding the 
inherent differences between CSCs and other cancer cell types through analyzing 
differences in biological networks in this complex pyramid. (Figure adapted from Oltvai ZN 
and Barabasi OL, (2002) Science 25, 763-764) 
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Following on the successes of molecular profiling in identifying prognostic signatures for 
many cancers, researchers have begun to perform profiling of CSCs as well (Cabanillas and 
Llorente 2009). Here we discuss such efforts in the context of different tumor models such as 
leukemia, brain, and breast. In addition to profiling for signatures of specific cancer stem 
cells, interesting work has also been done to find general signatures for “stemness” in 
tumors. For example, an 11 gene signature for “stemness” in multiple cancer types has been 
identified that predicts short interval to disease recurrence, distant metastasis and death 
from cancer (Glinsky et al. 2005). This signature/analysis reflects a BMI-1 oncogene-driven 
gene expression pathway, where the BMI-1 gene is essential for the self-renewal of 
hematopoietic and neural stem cells. Using retrospective survival analysis, this signature for 
“stem-ness” was found to show predictive ability in 11 different cancers, including epithelial 
cancers (prostate, breast, lung, ovarian, and bladder) and nonepithelial (lymphoma, 
mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia). Thus, there is 
evidence that the property of “stemness” (defined with this signature) is predictive of 
outcome in a wide variety of tumors. If validated, it is anticipated that the observations could 
have a major impact on patient care. Additionally, recent studies have indicated that cancer 
and normal stem cells share the same self-renewal mechanisms, such as the Bmi1 and Wnt 
canonical pathways (Reya and Clevers 2005), further strengthening the link between stem 
cells and cancer stem cells. However, it is expected that normal stem cells and cancer stem 
cells will have certain genotypic differences, which could be further exploited for designing 
targeted therapy for the elimination of CSCs without affecting normal stem cells. 
As mentioned earlier, tumor growth is generally accepted to be the result of several highly 
complex interacting processes. Fundamental cellular characteristics such as genetic and 
epigenetic features influence signal transduction activities that, in turn, control cellular 
functions. Additionally, environmental factors including nutrients and growth factor 
concentrations interplay with these processes. To study the emergent properties of such 
systems regarding proliferation speed, infiltrative growth, and phenotypical evolution of 
cancer, a number of advanced mathematical models have been developed (Anderson and 
Quaranta 2008). Using these models, some inroads have been made in understanding such 
hierarchical organized cancer cell populations on solid tumor growth dynamics and 
progression. In this study, it has been described that implementing the developing concept 
of CSCs in a mathematical tumor growth model directly results in an invasive morphology. 
Moreover, it was found that hierarchical organized malignant clones have highly altered 
evolutionary dynamics. Most strikingly, the CSC organization promotes phenotypical 
heterogeneity, a feature that could have immediate consequences for therapeutic resistance.  
4. Molecular networks of cancer stem cells 
Systems approaches to CSC characterization require not only the identification of the key 
components of a system through global analyses, but also require information about how 
these components interact in biological networks. Network models of multiple types have 
been applied to CSCs. The most commonly applied technique to CSC are interaction 
networks, including protein-protein interaction networks, protein-DNA interaction networks 
and so forth. Gene expression data can be used to identify differentially expressed genes 
which could then be visualized on interaction networks, as has been done for different 
cancers. Various properties of these networks have been studied, with reported findings 
including, for example, the enrichment of CSC related genes among the “hubs” of the 
networks. While these interaction networks are very useful tools for visualizing large data 
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sets, they are not computable whereas predictive network models could hold the most 
promise for predictive medicine and drug development. Predictive models stemming from 
mathematical descriptions of biochemical reaction networks and statistical influence 
models, where CSCs should prove highly useful and are currently being worked upon 
towards refinement.  
Another area of network modeling that should prove very beneficial in research of cancer 
and CSCs is that of metabolic networks. Key metabolic differences have been shown to exist 
in normal stem cells vs. CSCs which have been hypothesized to be exploited using Positron 
Emission Tomography (PET) to do in vivo imaging of tumors and even to predict treatment 
response. If key metabolic differences can be found between CSC and the rest of the tumor, 
such approaches could potentially even be used to identify the location of CSC populations 
in vivo. One enabling resource for large-scale quantitative modeling of metabolic networks 
in cancer is the recent stoichiometric reconstruction of known human metabolism at the 
genome-scale (Radrich et al. 2010). With this global reconstruction, gene expression and 
other data can be used to create initial models of the genome-scale metabolic networks of a 
variety of human cell types, including cancer stem cells. These biochemical reaction networks 
can be useful to make numerous quantitative simulations that have been shown previously 
to match well with experimental data in model organisms (Wilkinson 2009). These successes 
with model organisms have also been extended to models of simple systems in yeast to 
human erythrocyte models (Duarte et al. 2007; Duarte et al. 2004b; Duarte et al. 2004a), with 
the global metabolic reconstruction poised to allow for larger human metabolic networks 
that could now be modeled. These studies may well provide insights into the unique 
metabolic features of cancer cells—allowing one to identify both metabolic features that are 
shared among cancer cells and features that are unique to individual types of cancer. 
More detailed dynamic models of specific biochemical networks in cancer have been made 
for important signaling networks in cancer, leading to insightful biological observations that 
have been derived from among many others, the NF-κB signaling network (Lee and Covert 
2010; Tay et al. 2010; Covert et al. 2005; Hoffmann et al. 2002; Werner et al. 2005). As isolated 
CSC populations become better characterized, it will be possible to model these systems to 
identify differences in their regulation of CSCs and further identify possible therapeutic 
targets. Dynamic simulations of large-scale signaling networks in cancer cells have also been 
performed (Christopher et al. 2004). Large amounts of high-throughput data (i.e. 
transcriptomes) can be used to infer networks that can explain statistical dependencies seen 
in the data, indicating candidate novel interacting partners, and quantitatively predict the 
gene expression resulting from knockouts or environmental perturbation. For model 
systems, such approaches are now being successfully applied at the genome-scale for gene-
regulatory networks (Bonneau et al. 2006; Bonneau 2008; Hayete et al. 2007). Such approaches 
are now also being applied to mammalian systems as was done for normal and cancerous  
B-cells with the development of an algorithm called Reconstruction of Accurate Cellular 
Networks (ARACNe) (Basso et al. 2005; Basso and la-Favera 2007). As CSC populations are 
profiled extensively, these same approaches will be useful to identify predictive networks 
for CSCs. Comparing these networks to those in normal stem cells and other tumor cells 
should prove highly informative for identifying drug targets unique to the CSC population 
of interest. By generating networks of CSCs in particular and comparing them with 
networks of normal stem/progenitor cells, we should be able to greatly enhance our 
understanding that could lead to the characterization of cells that becomes cancerous. 
Computational modeling and systems approaches will be key to catalyzing the future of 
drug discovery (Hendriks 2010; Kumar et al. 2006; Hood and Perlmutter 2004), and thus 
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drug discovery focused specifically on CSCs offers tremendous promise for advancing 
cancer therapies. Therefore, computational modeling of CSC networks to identify potential 
therapeutic targets and to predict the effect of drug-induced perturbations is critical for this 
field moving forward. 
 
 
Fig. 4. Designing metabolic networks to understand CSCs: Datasets obtained from 
microarrays of regular cells and CSCs can be constructed to obtain complete metabolic 
networks. After refinement of these networks, validation can be done to differentiate key 
differences between these cells using molecular network silencing technologies. Finally the 
outcome can be correlated with literature based evidence 
5. Systems understanding of CSC response to therapeutic interventions 
Once the CSCs are indentified and causal link between CSC and tumor growth is 
established then the burning question would be how one can investigate the therapeutic 
intervention, tumor response and tumor relapse. It is well recognized that CSCs are more 
resistant to therapeutic interventions such as chemotherapy or irradiation compared with 
their differentiated counterparts (Jordan et al. 2006). More significantly, tumors that relapse 
after seemingly successful therapy are believed to regrow from the CSCs that survived the 
therapeutic regimen (Rich 2007; Rich and Bao 2007b). Recently, a number of studies have 
investigated the dynamics associated with therapeutic interventions that are either selective 
for CSCs or equally efficient against both cell types. It has been found that the morphology 
and growth kinetics of relapses for both types of therapeutic interventions are very much 
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different (Rich and Bao 2007a). Relapse after therapy that specifically targets non CSCs is 
accompanied by enhanced invasive growth patterns whereas relapsing tumors after 
stochastic tumor cell killing are similar to the malignancy before treatment. Simultaneously, 
in case CSCs are resistant to therapy, the pace at which the malignancy relapses is greatly 
enhanced due to the presence of relatively high fraction of CSCs directly following therapy. 
Also, the invasiveness of the recurrent tumors is markedly increased following intervention 
that is not effective against CSCs. These findings are in line with a range of clinical 
observations describing increased growth speed and enhanced invasion in the relapsing 
malignancy that are mostly attributed to the selection of more aggressive clones by the drug 
(Huff et al., 2006). Nevertheless, these observations could be partially explained by the 
failure of conventional therapies to eradicate the CSC compartment and the subsequent 
relapse dynamics in CSC-driven tumors. Furthermore, evaluation of evolutionary dynamics 
during relapse after both types of intervention reveals significant differences as well. 
Following therapy which is ineffective against CSCs, relapsing tumors display a marked 
increase in heterogeneity, whereas therapy that does target CSCs results in a dramatic 
decrease of heterogeneity (analyzed in article by Sottoriva et al 2010). This latter scenario is 
related to the fact that relapses are very much different compared with the primary 
malignancy with respect to the clonal lineages that contribute to the relapse of the tumor. In 
summary, these observations clearly indicate that applying therapy that is ineffectively 
targeting the CSC population is not only unsuccessful in curing the patient but would also 
promote malignant features including rapid expansion, increased invasion, and further 
stimulates heterogeneity directly after therapy. Therefore, overall understanding of the 
molecular expression differences and network modeling would allow for designing targeted 
therapy in the future for overcoming therapeutic resistance in order to eliminate tumor 
recurrence and metastasis. 
6. Conclusion  
The identification and prospective isolation of CSCs from leukemia, pancreatic and a 
number of other solid tumors has spawned a new paradigm in cancer research. Incremental 
progress has been made in understanding the critical differences between CSCs and other 
counterparts in the tumors, ranging from gene expression, protein expression, metabolic 
expression and microRNAs that are becoming emerging areas of network research. 
However, much needs to be learned on the differences between these cells in order to make 
progress towards the development of novel therapeutics that will specifically target CSCs 
but not the normal stem cells. Although traditional science has been helpful in understanding 
few differences but has been restricted to marker identification. In order to make substantial 
progress in characterization of these elusive cells, newer and integrated technologies are 
needed that take a holistic view of the cellular system in the context of tumor 
microenvironment. Systems biology along with molecular network modeling can be utilized 
with the goal of predictive, preventive, personalized, and participatory medicine for 
specifically targeting CSCs. This technology utilizes global assessment of cancer stem cells 
and their microenvironments (niche) at the level of complete transcriptome, proteome, and 
epigenome, using empowering new high throughput technologies. The resulting gene 
expression profile signatures of CSCs would serve as more accurate indicatives for cancer 
diagnosis and prognosis. Emerging proteomic technologies employing mass spectrometry 
and protein chip platforms would allow for identification of better cell-surface markers and 
their interaction with the resident stem cell niche, which will provide the potential 
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diagnostic markers from both body fluids and tumor tissues. Similar exploitation could also 
be done for microRNAs that are becoming important regulator of gene expression in tumors 
and body fluids. Although the systems biology methodologies are still developing and error 
prone, nevertheless, the initial version of the interactomes are of sufficient quality to provide 
insight into the differences between normal hematopoietic cell and CSCs. It is anticipated 
that incorporating these data into biological networks will provide fundament insights into 
the biology of CSCs and their abilities for self-renewal and differentiation. These combined 
efforts will ultimately lead to newer therapeutic strategy specifically by targeting CSCs for 
unprecedented design of personalized cancer therapy. 
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